Statin‐induced myasthenia: A disproportionality analysis of the WHO's VigiBase pharmacovigilance database. Issue 4 (29th July 2019)

• Record Type: Journal Article
• Authors: Gras‐Champel, Valerie; Batteux, Benjamin; Masmoudi, Kamel; Liabeuf, Sophie
• Is Part Of: Muscle & nerve. Volume 60:Issue 4(2019)
• Page Start: 382
• Page End: 386
• Publication Date: 2019-07-29
• Subjects: adverse drug reaction -- disproportionality -- myasthenia -- pharmacovigilance -- statin; Neuromuscular diseases -- Periodicals; Muscles -- Periodicals; Nerves -- Periodicals; 616.74
• DOI: 10.1002/mus.26637
• Languages: English
• ISSNs: 0148-639X

Abstract

Abstract: Background: Statins have been linked to myasthenia gravis (MG) in recent case reports. However, MG is not currently listed as an adverse drug reaction (ADR) in the summary of product characteristics. Methods: We performed case/noncase analyses in VigiBase® (the World Health Organization international database of suspected ADR) to identify a signal of MG (expressed as the reporting odds ratio [ROR] and its 95% confidence interval [CI]) for statins. Results: A total of 3967 reports mentioned MG. Of these, 169 were suspected to be statin‐induced. A disproportionality signal was found for MG and statins use (ROR [95%CI] = 2.66 [2.28–3.10]). Conclusions: The present disproportionality analysis revealed a possible drug safety signal linking MG and statins. This potential signal is weak, and is offset by the cardiovascular benefits of statins. Clinicians should be aware of this potential ADR, because it may require consideration of statin withdrawal or treatment of MG.